Ambrx is a clinical-stage biopharmaceutical company that utilizes a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). Their technology allows for the incorporation of synthetic amino acids into proteins, enabling site-specific, homogenous, and stable conjugation. This platform aims to overcome limitations of traditional conjugation technologies and create precision biologics with optimized safety and efficacy for treating various cancer indications.